<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325712</url>
  </required_header>
  <id_info>
    <org_study_id>1408-0002</org_study_id>
    <secondary_id>2017-003269-85</secondary_id>
    <nct_id>NCT03325712</nct_id>
  </id_info>
  <brief_title>This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 705564 (Double-blind, Randomised, Placebo-controlled, Parallel-group Design) and Evaluation of Midazolam Interaction (Nested, Open, Fixed-sequence, Intra-individual Comparison) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate safety and tolerability of BI 705564 in&#xD;
      healthy male subjects, following oral administration of multiple rising doses.&#xD;
&#xD;
      Secondary objectives are the exploration of the pharmacokinetics, including dose&#xD;
      proportionality and investigation of linearity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Actual">November 26, 2018</completion_date>
  <primary_completion_date type="Actual">November 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint to assess safety and tolerability of BI 705564 is the number [N (%)] of subjects with adverse reactions</measure>
    <time_frame>Up to day 27</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose) of BI 705564</measure>
    <time_frame>Up to day 1</time_frame>
    <description>After the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma) of BI 705564</measure>
    <time_frame>Up to day 1</time_frame>
    <description>After the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 705564</measure>
    <time_frame>Up to day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) of BI 705564</measure>
    <time_frame>Up to day 17</time_frame>
    <description>After the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma) of Midazolam (dose groups 2 to 5)</measure>
    <time_frame>Up to day 17</time_frame>
    <description>After the first and last doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) of Midazolam (dose groups 2 to 5)</measure>
    <time_frame>Up to day 17</time_frame>
    <description>After the first and last doses</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 705564</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Dose Group 1</arm_group_label>
    <arm_group_label>Dose Group 2</arm_group_label>
    <arm_group_label>Dose Group 3</arm_group_label>
    <arm_group_label>Dose Group 4</arm_group_label>
    <arm_group_label>Dose Group 5</arm_group_label>
    <arm_group_label>Dose Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dose Groups (DGs)1 to 5: Healthy male subjects according to the assessment of the&#xD;
             investigator, based on a complete medical history, a physical examination, vital signs&#xD;
             (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical&#xD;
             laboratory tests;&#xD;
&#xD;
          -  DG 8, only: Otherwise healthy male subjects (as defined for DGs 1 to 5) with a history&#xD;
             (of at least 1 year) of IgE-mediated, perennial allergies, predominantly to (house)&#xD;
             dust mite (dermatophagoides pteronyssinus or dermatophagoides farina) as documented by&#xD;
             a positive Skin prick test (SPT)(largest diameter of wheal at screening &gt; 5 mm)&#xD;
&#xD;
               -  Age of 18 to 50 years (incl.)&#xD;
&#xD;
               -  Body Max Index (BMI) of 18.5 to 29.9 kg/m2 (incl.)&#xD;
&#xD;
               -  Signed and dated written informed consent prior to admission to the study in&#xD;
                  accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR)&#xD;
             or Electrocardiogram (ECG)) is deviating from normal and judged as clinically relevant&#xD;
             by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 50 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease judged as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Cholecystectomy and/ or surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy and simple&#xD;
             hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizure or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to the trial&#xD;
             medication or its excipients)&#xD;
&#xD;
          -  Use of drugs within 30 days prior to administration of trial medication, if that might&#xD;
             reasonably influence the results of the trial (incl. QT/QTc interval prolongation)&#xD;
&#xD;
          -  Participation in another trial where an investigational drug has been administered&#xD;
             within 60 days prior to planned administration of trial medication, or current&#xD;
             participation in another trial involving administration of investigational drug.&#xD;
&#xD;
          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)&#xD;
&#xD;
          -  Inability to refrain from smoking on specified trial days&#xD;
&#xD;
          -  Alcohol abuse (consumption of more than 30 g per day)&#xD;
&#xD;
          -  Drug abuse or positive drug screening&#xD;
&#xD;
          -  Blood donation of more than 100 mL within 30 days prior to the administration of trial&#xD;
             medication or intended donation during the trial&#xD;
&#xD;
          -  Intention to perform excessive physical activities within one week prior to the&#xD;
             administration of trial medication or during the trial&#xD;
&#xD;
          -  Inability to comply with dietary regimen of the trial site&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are&#xD;
             repeatedly greater than 450 ms in males) or any other relevant Electrocardiogram (ECG)&#xD;
             finding at screening&#xD;
&#xD;
          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,&#xD;
             hypokalemia, or family history of Long QT Syndrome)&#xD;
&#xD;
          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,&#xD;
             because considered not able to understand and comply with study requirements, or has a&#xD;
             condition that would not allow safe participation in the study&#xD;
&#xD;
        In addition, the following trial-specific exclusion criteria apply:&#xD;
&#xD;
          -  Male subject with women of child bearing potential (WOCBP) partner who is unwilling to&#xD;
             use male contraception (condom or sexual abstinence) from the first administration of&#xD;
             trial medication until 30 days after last administration of trial medication&#xD;
&#xD;
          -  Subjects who, in the investigator's judgement, are perceived as having an increased&#xD;
             risk of bleeding, e.g. history of haemorrhagic disorders, clinical relevant petechial&#xD;
             bleeding, occult blood in faeces, haematuria in repeated urine tests, trauma or&#xD;
             surgery within the last month planned surgery during trial participation, history of&#xD;
             arteriovenous malformation or aneurysm, history of gastroduodenal ulcer disease or&#xD;
             gastrointestinal haemorrhage, history of intracranial, intraocular, spinal,&#xD;
             retroperitoneal, or atraumatic intraarticular bleeding, use of drugs that may&#xD;
             interfere with haemostasis during trial conduct (e.g. acetylic salicylic acid or other&#xD;
             non-steroidal anti-inflammatory drugs)&#xD;
&#xD;
          -  Repeated platelet counts below 100 cells/nL at screening&#xD;
&#xD;
          -  Bleeding times (to monitor platelet function) above reference range at screening&#xD;
&#xD;
          -  Repeated absolute B cell (CD19+) counts below 40/μL at screening&#xD;
&#xD;
          -  Serum potassium below normal range at screening&#xD;
&#xD;
          -  A history or current clinical signs of acute pancreatitis&#xD;
&#xD;
          -  Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

